Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK and Ligand strike licensing deal

This article was originally published in Scrip

Executive Summary

The US company Ligand Pharmaceuticalshas licensed the worldwide rights to its product candidate LGD-4665, a thrombopoietin (TPO) oral mimetic, and other TPO-related molecules toGlaxoSmithKline. GSK will pay Ligand an upfront licence fee worth $5 million, a further $158 million in development and commercial milestones and 16% royalty on net sales. Interim clinical study results show that LGD-4665 has potential efficacy for idiopathic thrombocytopenic purpura and for weekly dosing. The deal will allow Ligand to "prioritise its development expenses on other promising programmes going forward", says John Higgins, Ligand's president and CEO.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC008067

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel